Rewriting disease: Scripta Therapeutics targets the cell’s master switches
Longevity Technology - 17-Nov-2025Startup uses transcription factor mapping to find disease-modifying treatments for neurodegeneration
Peter Hamley
Former Chief Scientific Officer at Samsara Therapeutics, Advisory Board Member for UKI2S
Peter is CSO of Samsara Therapeutics, the world leading biotech in autophagy therapeutics, a vital cellular process which is implicated in longevity and many diseases including neurodegeneration. He spent more than a decade at Sanofi, in various global discovery and business development roles. He and his teams have contributed to the advancement of many projects into development across multiple therapeutic areas. He started his career at AstraZeneca after postdoctoral studies at the University of Pennsylvania, a PhD from Cambridge University, and a BSc in Chemistry from Imperial College London. He holds an MBA from the University of Bath.
Visit website: https://ukinnovationscienceseedfund.co.uk/our-team/dr-peter-hamley/
See also
Details last updated 19-Nov-2023
Peter Hamley News
Peter Hamley is also referenced in the following:
BSRA Annual Scientific Meeting 2024
04-Sep-2024
A compelling lineup of speakers from all areas of the biology of ageing (Birmingham, UK)
Global Healthspan Summit 2023
29-Nov-2023 to 30-Nov-2023
Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)
Longevity Startup Panel: Will you live forever?
14-Nov-2024
Longevity panel with Shakiba Kaveh, Peter Hamley and Brendan Swain organised by OSAL (FREE, London, UK)
